Tacrolimus dosing in Chinese renal transplant recipients: A population-based pharmacogenetics study

European Journal of Clinical Pharmacology

Volumn 67, Issue 8, 2011, Pages 787-795

  Li, Liang ^a   Li, Chuan Jiang ^a   Zheng, Lei ^a   Zhang, Yan Jun ^b   Jiang, Hai Xia ^a   Si Tu, Bo ^a   Li, Zhong Hai ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

Author keywords

CYP3A5; Dosing model; Pharmacogenetics; Renal transplantation; Tacrolimus

Indexed keywords

BILIRUBIN; TACROLIMUS;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CHINESE; CYTOCHROME P450 3A5 GENE; DOSE CALCULATION; FEMALE; GENETIC ASSOCIATION; GENOTYPE; GRAFT RECIPIENT; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE PROTEIN 1 GENE; NR112 GENE; PHARMACOGENETICS; PRIORITY JOURNAL; REGULATOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CHINA; COHORT STUDIES; CYTOCHROME P-450 CYP3A; DRUG MONITORING; GRAFT REJECTION; GRAFT SURVIVAL; HAPLOTYPES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MEDICAL RECORDS; MIDDLE AGED; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, STEROID; RETROSPECTIVE STUDIES; TACROLIMUS;

EID: 79960953221     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1010-y     Document Type: Article

References (31)

1. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF, ELITE-Symphony Study (2007) Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357:2562-75 (Pubitemid 350294223)
2. Kuypers DRJ, Claes K, Evenepoel P, Maes B, Vanrenterghem Y (2004) Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 75:434-47 (Pubitemid 38534564)
3. Masuda S, Inui K (2006) An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther 112:184
4. Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A, Kuypers D, Le Meur Y, Marquet P, Oellerich M, Thervet E, Toenshoff B, Undre N, Weber LT, Westley IS, Mourad M (2009) Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 31:139-52
5. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR (2004) Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5:243-72 (Pubitemid 38499965)
6. Roy JN, Barama A, Poirier C, Vinet B, Roger M (2006) CYP3A4, CYP3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics 16:659-65
7. Haufroid V, Wallemacq P, VanKerckhove V, Elens L, De Meyer M, Eddour DC, Malaise J, Lison D, Mourad M (2006) CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant 6:2706-13 (Pubitemid 44571691)
8. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM (2003) P-glycoprotein: from genomics to mechanism. Oncogene 22:7468-85 (Pubitemid 37487170)
9. Hesselink DA, van Gelder T, van Schaik RH (2005) The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics 6:323-37
10. Wang J, Zeevi A, McCurry K, Schuetz E, Zheng H, Iacono A, McDade K, Zaldonis D, Webber S, Watanabe RM, Burckart GJ (2006) Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors. Transpl Immunol 15:235-40 (Pubitemid 43129392)
11. Mai I, Perloff ES, Bauer S, Goldammer M, Johne A, Filler G, Budde K, Roots I (2004) MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol 58:548-53 (Pubitemid 39540460)
12. Fredericks S, Moreton M, Reboux S, Carter ND, Goldberg L, Holt DW, MacPhee IA (2006) Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. Transplantation 82:705-8 (Pubitemid 44395243)
13. Rosenfeld JM, Vargas R Jr, Xie W, Evans RM (2003) Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor. Mol Endocrinol 17:1268-82 (Pubitemid 36819950)
14. Benkali K, Prémaud A, Picard N, Rérolle JP, Toupance O, Hoizey G, Turcant A, Villemain F, Le Meur Y, Marquet P, Rousseau A (2009) Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet 48:805-16
15. Gonschior AK, Christians U, Winkler M, Linck A, Baumann J, Sewing KF (1996) Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. Clin Chem 42:1426-32 (Pubitemid 26300240)
16. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106:2329-33 (Pubitemid 41510803)
17. Tham LS, Goh BC, Nafziger A, Guo JY, Wang LZ, Soong R, Lee SC (2006) A warfarin dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther 80:346-55 (Pubitemid 44479750)
18. Jin Z, Zhang WX, Chen B, Mao AW, Cai WM (2009) Stepwise regression analysis of the determinants of blood tacrolimus concentrations in Chinese patients with liver transplant. Med Chem 5:301-4
19. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, Daly AK (2003) Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76:1233-5 (Pubitemid 37339651)
20. Katsakiori PF, Papapetrou EP, Sakellaropoulos GC, Goumenos DS, Nikiforidis GC, Flordellis CS (2010) Factors affecting the long-term response to tacrolimus in renal transplant patients: pharmacokinetic and pharmacogenetic approach. Int J Med Sci 7:94-100
21. Suzuki Y, Homma M, Doki K, Itagaki F, Kohda Y (2008) Impact of CYP3A5 genetic polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects. Br J Clin Pharmacol 66:154-5 (Pubitemid 351822158)
22. Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B, Beaune P, Legendre C, Thervet E (2003) Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 14:1889-96 (Pubitemid 36750485)
23. Mendes J, Martinho A, Simoes O, Mota A, Breitenfeld L, Pais L (2009) Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients. Transplant Proc 41:840-2
24. Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, Suzuki T, Habuchi T, Kato T (2004) Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 78:1182-7 (Pubitemid 39426437)
25. Haufroid V, Wallemacq P, VanKerckhove V, Elens L, De Meyer M, Eddour DC, Malaise J, Lison D, Mourad M (2006) CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant 6:2706-13 (Pubitemid 44571691)
26. Xiang Q, Zhao X, Zhou Y, Duan JL, Cui YM (2010) Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J Clin Pharmacol 50:659-66
27. Choi JH, Lee YJ, Jang SB, Lee JE, Kim KH, Park K (2007) Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. Br J Clin Pharmacol 64:185-91 (Pubitemid 47063248)
28. Undre NA, Schäfer A (1998) Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. Transplant Proc 30:1261-3 (Pubitemid 28309564)
29. Bellarosa C, Bortolussi G, Tiribelli C (2009) The role of ABC transporters in protecting cells from bilirubin toxicity. Curr Pharm Des 15:2884-92
30. Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, Toupance O, Touchard G, Alberti C, Le Pogamp P, Moulin B, Le Meur Y, Heng AE, Subra JF, Beaune P, Legendre C (2010) Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 87:721-6
31. Mathew BS, Fleming DH, Jeyaseelan V, Chandy SJ, Annapandian VM, Subbanna PK, John GT (2008) A limited sampling strategy for tacrolimus in renal transplant patients. Br J Clin Pharmacol 66:467-72